Drug observers puzzled by vaccine maker, which made a killing on COVID-19, failing to read the room with new administration. Moderna puts heat on FDA vaccines chief who's already been rebuked once by ...

The move is further in line with HHS Secretary Kennedy's anti-vaccine policies ...

Moderna (NASDAQ:MRNA) is escalating its standoff with US regulators at a delicate juncture in its post-pandemic reset. On Friday's analyst call, Chief Executive Officer Stephane Bancel described the ...

In a rare and surprising move, the FDA has issued a “Refusal to File” letter for Moderna’s mRNA-1010 influenza vaccine.

The FDA declined to review Moderna's mRNA influenza vaccine due to inadequate clinical trial comparators for older adults.

After a string of high-profile regulatory rebukes, Biohaven’s CEO believes red tape is getting in the way of patient ...

Moby Strategic Execution and Operational Pivot. Achieved a significant financial turning point in 2025 by reducing operating expenses ...

Moderna stock popped Friday after the company reported better-than-expected fourth-quarter sales and reiterated its 2026 outlook.

The rejection of Disc Medicine Inc.’s experimental compound for a rare and devastating disorder by the US Food and Drug Administration, just months after it received a voucher intended to speed US ...

The company is expecting additional readouts this year from studies of cancer vaccine intismeran autogene, which is being tested in late-stage trials.